Maike E Lindemann1, Axel Wetter2, Nika Guberina2, Bjoern Jakoby3, and Harald H Quick1,4
1Highfield and Hybrid MR Imaging, University Hospital Essen, Essen, Germany, 2Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany, 3Siemens MR, Siemens Healthcare GmbH, Erlangen, Germany, 4Erwin L. Hahn Institute for Magnetic Resonance Imaging, Essen, Germany
Synopsis
A potential challenge of using radiotracer 68-Ga-PSMA
for detection and staging of prostate cancer in PET/MR is a frequently observed
halo-artifact around the urinary bladder caused by improper scatter correction
(SC). Tumor manifestations in these regions might be non-detectable or show
distorted SUVs. To evaluate the impact of SC on 68-Ga-PSMA PET/MR imaging, PET
data sets of 100 patients were reconstructed twice using standard and improved
SC. The improved SC significantly reduces the halo-artifact around the bladder.
Measured SUVs in the halo margin on average increased by 325 %, and
therefore, considerably affect quantitative assessment of prostate cancer in
PET/MR.
Purpose:
Since the introduction of [68-Ga] gallium-labelled
prostate-specific membrane antigen (PSMA) ligand as positron emission
tomography (PET) tracer, several studies show promising results for the
detection of prostate cancer with PET/magnetic resonance imaging (MRI) [1-4]. A
potential challenge when using 68-Ga-PSMA for detection and staging of prostate
cancer is a frequently observed so-called “halo-artifact” or photopenic effect visible
in PET data often caused by improper scatter correction (SC) [5-7]. The halo-artifact
causes reduced signal intensity around the urinary bladder and at the levels of
the kidneys in scatter-corrected PET images (Fig. 1). Therefore, tumor
manifestations and PET active lesions in these regions might be non-detectable
or show distorted standardized-uptake-values (SUVs), thus hampering PET
quantification. The aim of this study is to investigate the impact of improved
SC on 68-Ga-PSMA PET quantification in PET/MR hybrid imaging of the prostate in
100 patients.
Methods:
PET scatter
correction typically employs a single Compton scatter simulation to compute a
scatter sinogram, which is scaled to the emission data to account for multiple
and possible external scatter from outside of the scanner’s field-of-view.
Eliminating the sometimes problematic renormalizing (rescaling) of the PET
emission image during the SC calculations for tracers like 68-Ga-PSMA can minimize
the appearance of the halo-artifact and therefore, improve diagnostic image quality
and PET quantification. To validate the impact of this “un-renormalized” SC on
68-Ga-PSMA PET/MR imaging, all 100 PET data sets were reconstructed twice: 1. standard
SC (software version VE11 SP1) serving as the reference standard, and 2. improved
un-renormalized SC (software version VE11 SP2). The presence and visibility of
halo-artifacts in PET data was rated in each reconstruction (grade 0 =
no halo-artifact, 1 = slight halo presence, 2 = moderate halo presence, 3 =
strong halo presence, and 4 = severe halo). SUVs were
measured in all detectable lesions, the bladder, the gluteus maximus and at the
halo-artifact margin. Relative differences between standard and improved
scatter correction were calculated.Results:
Table 1 shows the presence of halo-artifact rating in
grades for 100 patients. With standard SC the average grade is 2 (moderate halo-artifact),
whereas for improved SC the average grade is 0.9 (slight halo-artifact). With
improved SC in 23 patients no halo-artifact was visible and no PET data set
presented with a severe halo. In all 100 patients, the same number of congruent
lesions (74) was detected for both PET data reconstructions. Thus, no lesion
was completely missed-out due to halo-artifacts, independent of the scatter
correction method used. Changes in PET signal-to-noise-ratio and image noise
were statistically not significant. Bland-Altman plots (Fig. 2) show the
relative difference in measured SUVmean in the gluteus maximus, the
bladder, at the halo margin and in all detected lesions using standard and
improved scatter correction. The average increase in SUVmean in the
gluteus maximus using improved SC is 23.0 ± 9.2 % (mean ± SD) when compared to
the standard SC (SP1). The average increase in the bladder using improved SC is
7.1 ± 4.5 %. The average increase in SUVmean in the halo-margin
using SP2 is 325.4 ± 748.5 % when compared to SP1, the median is 127.3 %. The
average increase in all 74 detected lesions using improved SC is 12.4 ± 16.8 %.
All changes in SUVmean are statistically significant (p < 0.05).
Fig. 3 shows relative differences in SUVmean and SUVmax
between standard and improved scatter correction. Detected lesions were divided
into lesions detected inside (38 lesions) or outside (36 lesions) the halo
margin. The average increase using improved scatter correction in SUVmean
for lesions inside the halo-margin is 17.5 % and outside the halo-margin 6.9 %,
in SUVmax for lesions inside the halo margin is 7.4 % and
outside 3.5 %. Fig. 4 shows a patient example with relative difference
maps, PET data corrected with SP1 and SP1, MR data and fused images.
Halo-artifact was reduced from severe halo presence to no halo-artifact using
SP2. Relative differences up to 50 % in SUVmean in the lesions were
calculated. Discussion and Conclusion:
For quantitative PET/MR hybrid imaging of prostate
cancer using 68-Ga-PSMA a proper scatter correction is important to ensure best
possible diagnostic quality and PET quantification. The improved SC
significantly reduces the halo-artifact around the bladder. SUVs in the halo
margin increase averaged around 325 %, and therefore, considerably affect
the quantitative assessment of prostate cancer in PET/MR hybrid imaging. Acknowledgements
No acknowledgement found.References
[1] Eiber M, Nekolla SG, Maurer T, Weirich
G, Wester HJ, Schwaiger M. (68)Ga-PSMA PET/MR with multimodality image analysis
for primary prostate cancer. Abdom Imaging. 2015;40:1769-71.
[2] Afshar-Oromieh A, Haberkorn U, Schlemmer
HP et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled
PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.
Eur J Nucl Med Mol Imaging. 2014;41:887-97.
[3] Freitag MT, Radtke JP, Hadaschik BA et
al. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the
evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med
Mol Imaging. 2016;43:70-83.
[4] Lütje S, Blex S, Gomez B et al.
Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with
Local and Metastatic Prostate Cancer. PLoS
One. 2016;11:e0164392.doi:10.1371.
[5] Heußer
T, Mann P, Rank CM et al. Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.
PLoS One. 2017;12:doi:10.1371.
[6] Afshar-Oromieh A, Wolf M, Haberkorn U et
al. Effects of arm truncation on the appearance of the halo artifact in
68Ga-PSMA-11 (HBED-CC) PET/MRI. Eur J Nucl Med Mol Imaging. 2017;44:1636-46.
[7] Noto
B, Büther F, Auf der Springe K et al. Impact of PET acquisition durations on
image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI. EJNMMI
Res. 2017;7:12.doi:10.1186/s13550-017-0261-8.